GenScript Biotech Corporation, headquartered in Piscataway, N.J., has recently achieved an upgrade in its MSCI ESG rating from A to AA. This notable advancement by MSCI, a renowned index provider, highlights GenScript’s outstanding performance in product safety, quality, human capital development, and advancements in environmental and governance practices. The AA rating positions GenScript as a global leader in ESG practices within the biotech industry, demonstrating a strong commitment to sustainability and responsible business conduct.
MSCI’s ESG Ratings, which range from CCC to AAA, evaluate companies based on their exposure to industry-specific ESG risks and their ability to manage these risks effectively compared to their peers. GenScript’s upgraded rating reflects its proactive approach towards sustainability, aligning with its core mission of utilizing biotechnology to enhance the well-being of both people and nature. This recognition underscores the company’s dedication to creating long-term value for its stakeholders and investors worldwide, emphasizing the integration of sustainability into its core operations.
As a participant in the United Nations Global Compact (UNGC), GenScript upholds the Compact’s principles on human rights, labor, environment, and anti-corruption. Additionally, the company’s involvement with the Pharmaceutical Supply Chain Initiative (PSCI) underscores its commitment to promoting sustainable practices within the pharmaceutical industry. GenScript’s recent achievements, including a Silver Medal from EcoVadis, a “Low Risk” ESG rating from Morningstar Sustainalytics, and inclusion in the FTSE4Good Index Series, further validate its dedication to sustainable development and ethical business practices.
GenScript’s proactive stance on environmental sustainability is evident through its validation of carbon reduction targets by the Science Based Targets initiative (SBTi). By aligning its efforts with global climate change mitigation strategies, GenScript showcases its strong commitment to combating environmental challenges. The company’s continuous recognition on both national and international platforms solidifies its position as a leading biotech corporation dedicated to fostering sustainable growth and innovation within the industry.
Key Takeaways:
– GenScript Biotech’s MSCI ESG rating has been upgraded to AA, affirming its leadership in sustainability practices.
– The company’s participation in global initiatives like the UNGC and PSCI reflects its commitment to ethical business conduct.
– Validation of carbon reduction targets by SBTi underscores GenScript’s dedication to combating climate change.
– GenScript’s achievements in ESG ratings and sustainability initiatives highlight its position as a trusted global leader in biotechnology.
Tags: biotech
Read more on manilatimes.net